| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 32 | 2024 | 7738 | 1.140 |
Why?
|
| Pulmonary Embolism | 6 | 2015 | 343 | 0.990 |
Why?
|
| Coronary Angiography | 6 | 2014 | 672 | 0.910 |
Why?
|
| Multidetector Computed Tomography | 2 | 2015 | 154 | 0.890 |
Why?
|
| Fluorodeoxyglucose F18 | 13 | 2024 | 1253 | 0.830 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2024 | 858 | 0.810 |
Why?
|
| Diagnostic Errors | 3 | 2018 | 523 | 0.800 |
Why?
|
| Radiopharmaceuticals | 9 | 2019 | 1335 | 0.740 |
Why?
|
| Calcinosis | 4 | 2014 | 438 | 0.730 |
Why?
|
| Artifacts | 6 | 2015 | 539 | 0.700 |
Why?
|
| Heart | 7 | 2019 | 1255 | 0.700 |
Why?
|
| Positron-Emission Tomography | 10 | 2016 | 2210 | 0.580 |
Why?
|
| Pulmonary Artery | 4 | 2015 | 522 | 0.530 |
Why?
|
| Thoracic Wall | 3 | 2015 | 187 | 0.530 |
Why?
|
| Radiography, Thoracic | 8 | 2017 | 462 | 0.520 |
Why?
|
| Thoracic Neoplasms | 4 | 2007 | 343 | 0.490 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2015 | 611 | 0.480 |
Why?
|
| Myocardium | 3 | 2018 | 1335 | 0.480 |
Why?
|
| Lung Neoplasms | 21 | 2024 | 11817 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2022 | 7962 | 0.460 |
Why?
|
| Heart Neoplasms | 3 | 2015 | 215 | 0.390 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 418 | 0.380 |
Why?
|
| Coronary Vessels | 4 | 2011 | 692 | 0.380 |
Why?
|
| X-Ray Intensifying Screens | 1 | 2010 | 33 | 0.380 |
Why?
|
| Heart Diseases | 3 | 2019 | 756 | 0.370 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2019 | 1699 | 0.360 |
Why?
|
| Aortography | 1 | 2010 | 183 | 0.360 |
Why?
|
| Coronary Disease | 1 | 2014 | 811 | 0.360 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2015 | 909 | 0.350 |
Why?
|
| Contrast Media | 6 | 2010 | 1496 | 0.350 |
Why?
|
| Cardiomyopathies | 2 | 2017 | 622 | 0.350 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2010 | 166 | 0.330 |
Why?
|
| Incidental Findings | 1 | 2010 | 285 | 0.310 |
Why?
|
| Image Enhancement | 2 | 2008 | 568 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 12 | 2020 | 5466 | 0.290 |
Why?
|
| Neoplasms | 10 | 2019 | 15710 | 0.280 |
Why?
|
| Pleural Neoplasms | 2 | 2022 | 483 | 0.270 |
Why?
|
| Mesothelioma | 2 | 2022 | 557 | 0.260 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 1179 | 0.250 |
Why?
|
| Vascular Neoplasms | 3 | 2015 | 116 | 0.240 |
Why?
|
| Movement | 3 | 2019 | 564 | 0.230 |
Why?
|
| Venous Thrombosis | 2 | 2010 | 396 | 0.220 |
Why?
|
| Electrocoagulation | 1 | 2003 | 64 | 0.220 |
Why?
|
| Humans | 65 | 2024 | 270843 | 0.200 |
Why?
|
| Foreign Bodies | 1 | 2003 | 143 | 0.200 |
Why?
|
| Muscle, Skeletal | 2 | 2007 | 1328 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2007 | 959 | 0.180 |
Why?
|
| Thrombosis | 1 | 2007 | 816 | 0.180 |
Why?
|
| Respiratory-Gated Imaging Techniques | 1 | 2019 | 51 | 0.170 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 50 | 0.170 |
Why?
|
| Venous Thromboembolism | 2 | 2017 | 378 | 0.160 |
Why?
|
| Respiration | 2 | 2019 | 452 | 0.160 |
Why?
|
| Coronary Artery Disease | 4 | 2015 | 1094 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 3 | 2014 | 406 | 0.150 |
Why?
|
| Middle Aged | 31 | 2019 | 89535 | 0.150 |
Why?
|
| Mediastinal Neoplasms | 1 | 2022 | 427 | 0.150 |
Why?
|
| Tomography, Spiral Computed | 2 | 2010 | 133 | 0.150 |
Why?
|
| Tomography, Emission-Computed | 3 | 2008 | 324 | 0.130 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.130 |
Why?
|
| Male | 32 | 2019 | 127630 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 2495 | 0.130 |
Why?
|
| Sarcoma | 2 | 2006 | 1830 | 0.130 |
Why?
|
| Adult | 23 | 2017 | 80709 | 0.120 |
Why?
|
| Vascular Calcification | 1 | 2015 | 57 | 0.120 |
Why?
|
| Sensitivity and Specificity | 8 | 2015 | 5123 | 0.120 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2014 | 54 | 0.110 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 6196 | 0.110 |
Why?
|
| Pericardium | 3 | 2022 | 161 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 335 | 0.110 |
Why?
|
| Cardiology | 1 | 2019 | 585 | 0.110 |
Why?
|
| Female | 32 | 2019 | 147292 | 0.110 |
Why?
|
| Osteosarcoma | 2 | 2015 | 950 | 0.110 |
Why?
|
| Aged | 26 | 2017 | 72902 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 2123 | 0.100 |
Why?
|
| Radiography | 5 | 2007 | 1944 | 0.100 |
Why?
|
| Prevalence | 3 | 2017 | 3399 | 0.100 |
Why?
|
| Phantoms, Imaging | 2 | 2016 | 1314 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2009 | 1261 | 0.100 |
Why?
|
| Mediastinum | 2 | 2022 | 276 | 0.100 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 3241 | 0.100 |
Why?
|
| Retrospective Studies | 14 | 2017 | 39512 | 0.100 |
Why?
|
| Inhalation | 1 | 2011 | 43 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2017 | 1399 | 0.100 |
Why?
|
| Taxoids | 2 | 2011 | 994 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1470 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2008 | 949 | 0.090 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2010 | 79 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 221 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 230 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 303 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 5031 | 0.080 |
Why?
|
| Rabbits | 1 | 2010 | 978 | 0.080 |
Why?
|
| ROC Curve | 1 | 1992 | 1225 | 0.080 |
Why?
|
| Neoplasm Staging | 6 | 2022 | 13882 | 0.080 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 14506 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 247 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 7170 | 0.080 |
Why?
|
| Bone Neoplasms | 4 | 2015 | 2652 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 5176 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2011 | 16270 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 361 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2014 | 2868 | 0.070 |
Why?
|
| Aged, 80 and over | 11 | 2017 | 30813 | 0.070 |
Why?
|
| Adipose Tissue, Brown | 2 | 2005 | 114 | 0.070 |
Why?
|
| Sirolimus | 1 | 2011 | 834 | 0.070 |
Why?
|
| Radiology | 1 | 1992 | 451 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2010 | 501 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2008 | 4862 | 0.070 |
Why?
|
| Aorta | 1 | 2010 | 707 | 0.070 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2006 | 89 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2013 | 1852 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 102 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 658 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1598 | 0.070 |
Why?
|
| Heart Atria | 1 | 2008 | 367 | 0.060 |
Why?
|
| Pulmonary Fibrosis | 1 | 2006 | 176 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 5116 | 0.060 |
Why?
|
| Prognosis | 3 | 2024 | 22249 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 15198 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 1997 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2019 | 303 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2013 | 1369 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6269 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2011 | 2319 | 0.060 |
Why?
|
| Electrodes | 1 | 2003 | 117 | 0.060 |
Why?
|
| Observer Variation | 3 | 2015 | 708 | 0.050 |
Why?
|
| Research Design | 1 | 2010 | 1598 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2008 | 896 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 238 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 182 | 0.050 |
Why?
|
| Incidence | 3 | 2020 | 5904 | 0.050 |
Why?
|
| Lung | 2 | 2011 | 3245 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1502 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 3974 | 0.050 |
Why?
|
| Pleura | 1 | 2022 | 128 | 0.050 |
Why?
|
| Carboplatin | 3 | 2010 | 844 | 0.050 |
Why?
|
| Smoking | 1 | 2010 | 2525 | 0.050 |
Why?
|
| Lung Injury | 1 | 2002 | 136 | 0.050 |
Why?
|
| Thymoma | 1 | 2003 | 250 | 0.040 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 2352 | 0.040 |
Why?
|
| Ventricular Dysfunction | 1 | 2019 | 33 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2003 | 413 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 1348 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 232 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2019 | 161 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 161 | 0.040 |
Why?
|
| Radioisotopes | 1 | 2017 | 178 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 16053 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2002 | 908 | 0.040 |
Why?
|
| Adolescent | 4 | 2015 | 32336 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2007 | 361 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 156 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 3518 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1449 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 1899 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 2273 | 0.030 |
Why?
|
| Neoplasms, Vascular Tissue | 2 | 2003 | 10 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 302 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 13310 | 0.030 |
Why?
|
| Peripheral Nervous System Neoplasms | 2 | 2003 | 72 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 61014 | 0.030 |
Why?
|
| Liver | 1 | 2002 | 2990 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2012 | 199 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 9010 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2012 | 201 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2017 | 858 | 0.020 |
Why?
|
| Heart Rate | 1 | 2014 | 752 | 0.020 |
Why?
|
| Biological Transport | 1 | 2012 | 605 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 180 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 165 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 360 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 242 | 0.020 |
Why?
|
| Quality Control | 1 | 2011 | 461 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2019 | 2428 | 0.020 |
Why?
|
| Everolimus | 1 | 2011 | 419 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 7908 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2009 | 232 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 484 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1576 | 0.020 |
Why?
|
| Risk Factors | 2 | 2019 | 18267 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 552 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 4925 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 74 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 1314 | 0.020 |
Why?
|
| Niacinamide | 1 | 2009 | 423 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 95 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 372 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 4062 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2012 | 9324 | 0.020 |
Why?
|
| Surface Properties | 1 | 2007 | 185 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 987 | 0.020 |
Why?
|
| Microcomputers | 1 | 2006 | 38 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 4452 | 0.020 |
Why?
|
| Methotrexate | 1 | 2010 | 1024 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2006 | 89 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 329 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1335 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 677 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 947 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2006 | 142 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1025 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2007 | 335 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2005 | 102 | 0.020 |
Why?
|
| Glutamates | 1 | 2005 | 131 | 0.020 |
Why?
|
| Bleomycin | 1 | 2006 | 478 | 0.020 |
Why?
|
| Guanine | 1 | 2005 | 152 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6245 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2217 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 2019 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 184 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 7704 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2015 | 16792 | 0.010 |
Why?
|
| Young Adult | 2 | 2015 | 22140 | 0.010 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 124 | 0.010 |
Why?
|
| Indoles | 1 | 2009 | 1021 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 2005 | 182 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 9487 | 0.010 |
Why?
|
| Lipids | 1 | 2007 | 661 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 834 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 130 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 3059 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 3522 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 734 | 0.010 |
Why?
|
| Disease Progression | 2 | 2005 | 6891 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 1569 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 1129 | 0.010 |
Why?
|
| Time Factors | 2 | 2007 | 13266 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 2056 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 2002 | 47 | 0.010 |
Why?
|
| Mass Screening | 1 | 2010 | 1568 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 589 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 1354 | 0.010 |
Why?
|
| Diaphragm | 1 | 2002 | 183 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 1269 | 0.010 |
Why?
|
| Child | 2 | 2015 | 30200 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 1429 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3363 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10093 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5930 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 2117 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4462 | 0.010 |
Why?
|
| Biomarkers, Tumor | 2 | 2006 | 10627 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 3988 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 7173 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 5239 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12451 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 7429 | 0.010 |
Why?
|
| United States | 1 | 2010 | 16339 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 5531 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 1927 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 4995 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 10257 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 4776 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 35331 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 34238 | 0.000 |
Why?
|